Shijun Kang

4.6k total citations · 1 hit paper
22 papers, 3.0k citations indexed

About

Shijun Kang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Shijun Kang has authored 22 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Shijun Kang's work include Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Shijun Kang is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Shijun Kang collaborates with scholars based in China and United States. Shijun Kang's co-authors include Jonathan D. Cheng, Terrill K. McClanahan, Mark Ayers, Jennifer H. Yearley, Andrew Albright, David R. Kaufman, Jared Lunceford, Michael Nebozhyn, Tanguy Y. Seiwert and Veena Shankaran and has published in prestigious journals such as Journal of Clinical Investigation, Biochemical and Biophysical Research Communications and FEBS Letters.

In The Last Decade

Shijun Kang

22 papers receiving 2.9k citations

Hit Papers

IFN-γ–related mRNA profil... 2017 2026 2020 2023 2017 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
    2017 2.3k citations Mark Ayers, Jared Lunceford et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shijun Kang China 12 2.0k 1.2k 881 853 552 22 3.0k
Jonathan J. Havel United States 13 1.9k 0.9× 1.1k 0.9× 825 0.9× 683 0.8× 493 0.9× 14 2.7k
Kaoru Abiko Japan 25 2.4k 1.2× 1.8k 1.6× 965 1.1× 591 0.7× 557 1.0× 102 4.0k
Marleen Kok Netherlands 30 2.3k 1.1× 953 0.8× 1.1k 1.2× 817 1.0× 887 1.6× 90 3.6k
Khalid Al‐Shibli Norway 28 1.8k 0.9× 916 0.8× 1.3k 1.5× 810 0.9× 979 1.8× 44 3.2k
Hiroko Asanuma Japan 32 1.4k 0.7× 782 0.7× 1.2k 1.4× 520 0.6× 406 0.7× 63 2.6k
Yuping Sun China 27 1.3k 0.7× 831 0.7× 818 0.9× 502 0.6× 413 0.7× 87 2.4k
Laurence Buisseret Belgium 21 2.6k 1.3× 1.6k 1.4× 684 0.8× 657 0.8× 589 1.1× 65 3.6k
Su Yin Lim Australia 28 1.6k 0.8× 1.4k 1.2× 1.3k 1.4× 415 0.5× 474 0.9× 50 3.1k
Zachary Boyd United States 14 2.3k 1.2× 1.2k 1.0× 1.1k 1.2× 650 0.8× 731 1.3× 27 3.7k
Takuya Tsunoda Japan 33 1.6k 0.8× 1.4k 1.2× 1.3k 1.5× 382 0.4× 355 0.6× 162 3.1k

Countries citing papers authored by Shijun Kang

Since Specialization
Citations

This map shows the geographic impact of Shijun Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shijun Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shijun Kang more than expected).

Fields of papers citing papers by Shijun Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shijun Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shijun Kang. The network helps show where Shijun Kang may publish in the future.

Co-authorship network of co-authors of Shijun Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Shijun Kang. A scholar is included among the top collaborators of Shijun Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shijun Kang. Shijun Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Zike, Huita Wu, Qing Lin, Xin Wang, & Shijun Kang. (2022). Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma. Immunology Letters. 250. 15–22. 5 indexed citations
2.
Zhang, Jiexia, Ningning Zhou, Anqi Lin, et al.. (2020). ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunology Immunotherapy. 70(1). 137–151. 67 indexed citations
3.
4.
5.
Hu, Guolin, Jialü Zhang, Feifei Xu, et al.. (2018). Stomatin‐like protein 2 inhibits cisplatin‐induced apoptosis through MEK/ERK signaling and the mitochondrial apoptosis pathway in cervical cancer cells. Cancer Science. 109(5). 1357–1368. 32 indexed citations
6.
Yang, Zike, Jiahe Zhang, Zehong Chen, et al.. (2018). Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. Journal of Experimental & Clinical Cancer Research. 37(1). 1–1. 258 indexed citations
7.
8.
Ayers, Mark, Jared Lunceford, Michael Nebozhyn, et al.. (2017). IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation. 127(8). 2930–2940. 2342 indexed citations breakdown →
9.
Yang, Zike, et al.. (2016). Small interfering RNA (siRNA)-mediated knockdown of Notch1 suppresses tumor growth and enhances the effect of IL-2 immunotherapy in malignant melanoma.. PubMed. 20(6). 1553–64. 4 indexed citations
10.
Zhang, Junyi, et al.. (2014). TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma. Cancer Letters. 354(1). 200–209. 10 indexed citations
11.
Kang, Shijun, et al.. (2012). A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response. Cancer Immunology Immunotherapy. 62(1). 183–190. 15 indexed citations
12.
Kang, Shijun, et al.. (2009). Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology. 215(2). 153–162. 32 indexed citations
13.
Kang, Shijun, Chunlan Yang, & Rongcheng Luo. (2008). Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochemical and Biophysical Research Communications. 372(4). 629–633. 8 indexed citations
14.
Qin, Jing, Penghai Zhang, Xinyu Qian, et al.. (2008). [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].. PubMed. 28(6). 930–2. 3 indexed citations
15.
Kang, Shijun, Rongcheng Luo, Yoel Smicun, David A. Fishman, & Yuru Meng. (2005). Selective induction of cyclooxygenase‐2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS Letters. 580(2). 443–449. 11 indexed citations
16.
Meng, Yuru, Shijun Kang, & David A. Fishman. (2005). Lysophosphatidic acid inhibits anti‐Fas‐mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS Letters. 579(5). 1311–1319. 15 indexed citations
17.
Meng, Yuru, Shijun Kang, & David A. Fishman. (2005). Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer Immunology Immunotherapy. 54(8). 807–814. 34 indexed citations
18.
Meng, Yuru, Shijun Kang, John So, Scott Reierstad, & David A. Fishman. (2004). Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecologic Oncology. 96(2). 462–469. 26 indexed citations
19.
20.
Liao, Wangjun, Rongcheng Luo, Shijun Kang, et al.. (2002). [Investigation of short-term therapy results for radiofrequency ablation by positron emission tomography].. PubMed. 22(4). 376–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan J. Havel Breakdown of academic impact, for papers by Kaoru Abiko Breakdown of academic impact, for papers by Marleen Kok Breakdown of academic impact, for papers by Khalid Al‐Shibli Breakdown of academic impact, for papers by Hiroko Asanuma Breakdown of academic impact, for papers by Yuping Sun Breakdown of academic impact, for papers by Laurence Buisseret Breakdown of academic impact, for papers by Su Yin Lim Breakdown of academic impact, for papers by Zachary Boyd Breakdown of academic impact, for papers by Takuya Tsunoda
Rankless by CCL
2026